Asterias Biotherapeutics Inc (NYSE:AST) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “

Other analysts have also issued research reports about the company. Laidlaw started coverage on Asterias Biotherapeutics in a research note on Tuesday, April 4th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Asterias Biotherapeutics in a research report on Thursday, March 30th.

Shares of Asterias Biotherapeutics (NYSE:AST) traded down 2.86% during trading on Tuesday, reaching $3.40. 83,776 shares of the company’s stock traded hands. The company’s 50-day moving average is $3.34 and its 200 day moving average is $3.68. The company’s market cap is $167.49 million. Asterias Biotherapeutics has a 52-week low of $2.54 and a 52-week high of $5.80.

TRADEMARK VIOLATION WARNING: “Asterias Biotherapeutics Inc (AST) Stock Rating Lowered by Zacks Investment Research” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Get a free copy of the Zacks research report on Asterias Biotherapeutics (AST)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with's FREE daily email newsletter.